alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit
      23.1





**CONSENT
        OF REGISTERED INDEPENDENT PUBLIC ACCOUNTING FIRM**
 
 We
        hereby
        consent to the incorporation by reference in Registration Statement No.
        333-69460 and Registration Statement No. 333-141555 on Form S-8 of our report
        dated March 7, 2008 relating to the consolidated balance sheets of Chembio
        Diagnostics Inc. and Subsidiaries as of December 31, 2007 and 2006 and the
        consolidated statements of operations, stockholders’ equity (deficit) and cash
        flows for the two years in the period ended December 31, 2007 appearing in
        this
        Annual Report on Form 10-KSB of Chembio Diagnostics, Inc. for the year ended
        December 31, 2007.
 
 
 
 /s/Lazar
        Levine & Felix LLP
 
 New
        York,
        New York
 March
        11,
        2008
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2042 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                H. R. 2042

   To provide for a limitation on availability of funds for Related 
     Agencies, National Council on Disability for fiscal year 2024.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 29, 2023

Mr. Biggs (for himself, Mr. Rosendale, Mr. Gaetz, Mr. Good of Virginia, 
   Mr. Roy, and Mr. Crane) introduced the following bill; which was 
        referred to the Committee on Education and the Workforce

_______________________________________________________________________

                                 A BILL

 
   To provide for a limitation on availability of funds for Related 
     Agencies, National Council on Disability for fiscal year 2024.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. LIMITATION ON AVAILABILITY OF FUNDS FOR RELATED AGENCIES, 
              NATIONAL COUNCIL ON DISABILITY FOR FISCAL YEAR 2024.

    Notwithstanding any other provision of the law, amounts authorized 
to be appropriated or otherwise available for Related Agencies, 
National Council on Disability for fiscal year 2024 may not exceed 
$3,250,000.
                                 <all>
```
**EXHIBIT 21.1**

**SUBSIDIARIES OF SYCAMORE NETWORKS, INC.**

SycamoreNetworks Asia Inc. 

Delaware 

Sycamore Networks Europe Inc. 

Delaware 

Sycamore Networks Real Estate, LLC 

Delaware 

Sycamore Networks Americas Inc. 

Delaware 

SycamoreSecurities Corporation 

Massachusetts 

Sycamore Bach LLC 

Pennsylvania 

Sycamore Networks International BV 

Amsterdam, The Netherlands 

Sycamore Networks (Shanghai) Co., Ltd. 

People’s Republic of China 

Sycamore Networks Japan K.K. 

Japan
**Exhibit
      32.1**





CERTIFICATION
      PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002





In
      condition with the Quarterly Report on Form 10-Q of Polydex Pharmaceuticals
      Limited (the “Company”) for the fiscal quarter ended October 31, 2005 as filed
      with the Securities and Exchange Commission on the date hereof (the “Report”),
      I, George G. Usher, Chief Executive Officer of the Company, certify, pursuant
      to
      18 U.S.C. 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act
      of
      2002, that:





(1)
      the
      Report fully complies with the requirements of section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and





(2)
      the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and result of operations of the Company.








By /s/
      George G. Usher


George
      G.
      Usher,


Chief
      Executive Officer


December
      14, 2005





This
      certification accompanies this Report pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for
      purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
      “Exchange Act”). This certification shall not be deemed to be incorporated by
      reference into any filing under the Securities Act of 1933, as amended, or
      the
      Exchange Act, except to the extent that the Company specifically incorporates
      it
      by reference.





A
      signed
      original of this written statement required by section 906 has been provided
      to
      the Company and will be retained by the Company and furnished to the Securities
      and Exchange Commission or its staff upon request.
#### Jimmy DUNCAN, a/k/a Jimmy L. Duncan, Plaintiff-Appellant, v. N. GORDON, Sergeant, Lee Correctional Institution; Jane Doe, a/k/a NFN Slade, Nurse, Lee Correctional Institution; Jane Doe, a/k/a NFN Robinson, Nurse, Lee Correctional Institution; Officer Anderson, NFN, Lee Correctional Institution; Officer Dubose, NFN, Lee Correctional Institution; Officer Brunson, NFN, Lee Correctional Institution; Sergeant Roberts, a/k/a NFN Robertson, NFN, Lee Correctional Institution, Defendants-Appellees.

No. 07-7296.

United States Court of Appeals, Fourth Circuit.

Submitted: Dec. 20, 2007.

Decided: Dec. 28, 2007.

Jimmy Duncan, Appellant Pro Se. John Evans James, III, Lee, Erter, Wilson, James, Holler & Smith, LLC, Sumter, South Carolina, for Appellees.

Before MICHAEL and KING, Circuit Judges, and HAMILTON, Senior Circuit Judge.

Affirmed by unpublished PER CURIAM opinion.

Unpublished opinions are not binding precedent in this circuit.

PER CURIAM:

Jimmy Duncan appeals the district court’s order accepting the recommendation of the magistrate judge and denying relief on his 42 U.S.C. § 1983 (2000) complaint, and a subsequent order denying his motion to alter or amend judgment and motion to stay. We have reviewed the record and find no reversible error. Accordingly, we affirm for the reasons stated by the district court. *Duncan v. Gordon,*No. 8:06-cv-00396-MBS, 2007 WL 1031939 (D.S.C. Mar. 29, 2007; filed July 11, 2007 & entered July 12, 2007). We further deny Duncan’s motions to authorize preparation of transcript at government expense and for default judgment. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before *544the court and argument would not aid the decisional process.

*AFFIRMED.*
#### The People of the State of New York, Appellant, v Benjamin Sherman, Respondent.

[825 NYS2d 770]

Appeal by the People from an order of the Supreme Court, Kings County (Firetog, J.), dated February 10, 2006, which granted the defendant’s motion to dismiss the indictment in furtherance of justice pursuant to CPL 210.40.

Ordered that the order is reversed, as a matter of discretion, the motion is denied, the indictment is reinstated, and the matter is remitted to the Supreme Court, Kings County, for further proceedings on the indictment.

“The discretionary authority to dismiss an indictment in furtherance of justice [pursuant to CPL 210.40] should be ‘exercised sparingly’ and only in ‘those rare cases where there is a “compelling factor” which clearly demonstrates that prosecution of the indictment would be an injustice’ ” *(People v Ward,*300 AD2d 418 [2002], quoting *People v Flemming,*291 AD2d 506 [2002], quoting CPL 210.40 [1]). This is not one of those "rare" cases.

*769Although the defendant was diagnosed in 2002 with a serious medical condition, there is no evidence that his status has significantly deteriorated, and his survival prognosis is unclear. His condition does not constitute a “compelling factor” (CPL 210.40 [1]) which, by itself or in conjunction with all of the other circumstances of this case, warranted “the extraordinary remedy of dismissal of the indictment in the furtherance of justice” *(People v Scott,*12 AD3d 383 [2004], quoting *People v Moye,*302 Ad2d 610, 611 [2003]). We also note that the defendant has an extensive criminal record *(see People v Moye, supra).*

Accordingly, giving due consideration to all of the circumstances of this case, as well as the criteria set forth in CPL 210.40, we conclude that the defendant failed to establish the existence of any “compelling factor” which justified dismissal of the indictment pursuant to CPL 210.40 *(see People v McAlister,*280 AD2d 556 [2001]; *People v Tavares,*273 AD2d 707 [2000]). Prudenti, P.J., Schmidt, Dillon and Covello, JJ., concur.
2015 Q2 FES - EX 10.1




EXHIBIT 10.1
FIRST AMENDMENT TO 
EMPLOYMENT AGREEMENT
This First Amendment to Employment Agreement (this "Amendment") is made effective as of July 30, 2015 by and between Forbes Energy Services LLC, a Delaware limited liability company (the "Company"), and John E. Crisp an individual (the “Employee”).
WHEREAS, the parties hereto entered into that certain Employment Agreement effective as of May 1, 2008 (the “Agreement”)
WHEREAS, the parties desire to amend the Agreement in order to clarify the confidentially and non-disclosure obligations of the Employee; 
NOW THEREFORE, in consideration of the premises set forth above, the parties hereby agree as follows:
		
	1.
	The following language will be added as the last paragraph of Section 11 of the Agreement:


		
	a.
	“Notwithstanding anything herein to the contrary, or in any agreement or communication between Employer and Employee, (a) the confidentiality and non-disclosure obligations herein shall not prohibit or restrict Employee from initiating communications directly with, or responding to any inquiry from, or providing testimony before, the SEC, any other governmental agency, any self-regulatory organization or any other state or federal regulatory authority, regarding any possible securities law violations, and (b) Employer shall not enforce or threaten to enforce, any confidentiality agreement or other similar agreement, nor take or threaten to take any other action against Employee for engaging in the types of communications described in (a) above.”


		
	2.
	Except to the extent set forth herein, the Agreement shall remain in full force and effect.


		
	3.
	This Amendment may be executed in one or more counterparts, and signature pages may be delivered by facsimile, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, and shall become effective upon its execution by the parties hereto.


[Signature Page Follows]







IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.  
COMPANY: 
 
FORBES ENERGY SERVICES LLC  
 
 
By:    /s/ L. Melvin Cooper     
    L. Melvin Cooper, Chief Financial Officer 
 
 
EMPLOYEE: 
 
JOHN E. CRISP 
 
 
By:    /s/ John E. Crisp     
    John E. Crisp
#### In the Matter of James Oliver, Petitioner, v Brian Fischer, as Commissioner of Corrections and Community Supervision, Respondent.

[967 NYS2d 248]

Proceeding pursuant to CPLR article 78 (transferred to this Court by order of the Supreme Court, entered in Albany County) to review a determination of respondent which found petitioner guilty of violating a prison disciplinary rule.

During a search of petitioner’s cell, a correction officer found what appeared to be a partially-smoked marihuana cigarette. The item was recovered and tested, but the results were negative for marihuana. Nevertheless, petitioner was charged in a misbehavior report with possessing contraband. He was found guilty of the charge following a tier III disciplinary hearing and the determination was affirmed on administrative appeal. This CPLR article 78 proceeding ensued.

We confirm. The misbehavior report and related documenta*1269tion, together with the testimony adduced at the hearing, provide substantial evidence supporting the determination of guilt *(see Matter of Jamison v State of N.Y. Dept. of Corr. Servs.,*98 AD3d 1150, 1150 [2012]; *Matter of Alache v Fischer,*91 AD3d 1240, 1241 [2012]). Based upon prior experience, the correction sergeant who endorsed the misbehavior report identified the substance as synthetic marihuana also known as “spice,” which inmates are not permitted to possess. Notably, the disciplinary rule in question prohibits inmates from possessing “any item unless it has been specifically authorized by the superintendent or designee, the rules of the department or the local rules of the facility” (7 NYCRR 270.2 [B] [14] [xiii]). Although petitioner maintained that he did not possess synthetic marihuana, this presented a credibility issue for the Hearing Officer to resolve *(see Matter of Amen v James,*98 AD3d 772, 773 [2012]; *Matter of Perez v Fischer,*69 AD3d 1279, 1279-1280 [2010]). In view of the foregoing, the determination is supported by substantial evidence and we decline to disturb it.

Stein, J.P., McCarthy, Garry and Egan Jr., JJ., concur. Adjudged that the determination is confirmed, without costs, and petition dismissed.
**EXHIBIT
      32.1**





CERTIFICATION
      PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002





In
      condition with the Quarterly Report on Form 10-Q of Polydex Pharmaceuticals
      Limited (the “Company”) for the fiscal quarter ended October 31, 2006 as filed
      with the Securities and Exchange Commission on the date hereof (the “Report”),
      I, George G. Usher, Chief Executive Officer of the Company, certify, pursuant
      to
      18 U.S.C. 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act
      of
      2002, that:





(1)
      the
      Report fully complies with the requirements of section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and





(2)
      the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and result of operations of the Company.







By: /s/
      George G. Usher


George
      G.
      Usher,


Chief
      Executive Officer


December
      14, 2006





A
      signed
      original of this written statement required by section 906 has been provided
      to
      the Company and will be retained by the Company and furnished to the Securities
      and Exchange Commission or its staff upon request.
#### In the Matter of Arkil Lionkingzulu, Petitioner, v Brian Fischer, as Commissioner of Corrections and Community Supervision, et al., Respondents.

[966 NYS2d 703]

Proceeding pursuant to CPLR article 78 (transferred to this Court by order of the Supreme Court, entered in Albany County) to review a determination of respondent Commissioner of Corrections and Community Supervision which found petitioner guilty of violating certain prison disciplinary rules.

Following a melee in the prison exercise yard, petitioner was charged in a prison misbehavior report with fighting, refusing a direct order and engaging in violent conduct. He was found guilty as charged following a tier III disciplinary hearing and, *upon*administrative appeal, that determination was affirmed. Petitioner thereafter commenced this CPLR article 78 proceeding.

We confirm. The detailed misbehavior report and unusual incident report provide substantial evidence to support the determination of guilt *(see Matter of Encarnacion v Bellnier,*89 AD3d 1301, 1302 [2011]; *Matter of James v Fischer,*67 AD3d 1163, 1163 [2009]). Contrary to petitioner’s contention, nothing in a video recording of the altercation contradicted the claim that he was a combatant in it *(see Matter of McLaughlin v Fischer,*69 AD3d 1071, 1072 [2010]). His remaining claim has been considered and found to be without merit.

Peters, P.J., Rose, McCarthy and Egan Jr., JJ., concur. Adjudged that the determination is confirmed, without costs, and petition dismissed.
----

Exhibit 31.1 

CERTIFICATION 

I, George G. Usher, Chief Executive Officer ofPolydex Pharmaceuticals Limited (the "Company") certify that: 

1.

Ihave reviewed this quarterly report on Form 10–Q of the Company for the fiscalquarter ended October 31, 2007; 

2.

Based on my knowledge, this quarterly report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the Company as of, and for,the period presented in this report; 

4.

TheCompany’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules13a–15(e) and 15d–15(e) and internal control over financial reporting (asdefined in Exchange Act Rules 13a-15(f)) and 15d-15(f)) for the Company andhave: 

(a)

designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure thatmaterial information relating to the Company, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report was being prepared; 

(b)

evaluated the effectiveness of the Company’s disclosure controls and proceduresand presented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and 

(c)

disclosed in this report any change in the Company’s internal control overfinancial reporting that occurred during the Company’s most recent fiscalquarter that has materially affected, or is reasonably likely to materiallyaffect the Company’s internal control over financial reporting; and 

5.

TheCompany’s other certifying officer and I have disclosed, based on our mostrecent evaluation, to the Company’s auditors and the audit committee of theCompany’s board of directors: 

(a)

allsignificant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely toadversely affect the Company’s ability to record, process, summarize and reportfinancial information; and 

(b)

anyfraud, whether or not material, that involves management or other employees whohave a significant role in the Company’s internal control over financialreporting. 

Dated: December 14, 2007 

 

/s/ George G. Usher                                

Chief Executive Officer 

Polydex Pharmaceuticals Limited 

 

----
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
ACCOMPANYING FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-2000
<PERIOD-START>                              OCT-1-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                       1,206,096
<SECURITIES>                                         0
<RECEIVABLES>                                  261,671
<ALLOWANCES>                                    40,000
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,427,767
<PP&E>                                       2,539,390
<DEPRECIATION>                               2,283,683
<TOTAL-ASSETS>                               2,355,790
<CURRENT-LIABILITIES>                          693,428
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        16,276
<OTHER-SE>                                   1,646,086
<TOTAL-LIABILITY-AND-EQUITY>                 2,355,790
<SALES>                                              0
<TOTAL-REVENUES>                             1,331,641
<CGS>                                                0
<TOTAL-COSTS>                                  813,270
<OTHER-EXPENSES>                             3,635,670
<LOSS-PROVISION>                              (40,000)
<INTEREST-EXPENSE>                               9,811
<INCOME-PRETAX>                              3,087,110
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          3,087,110
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (3,087,110)
<EPS-BASIC>                                      (.20)
<EPS-DILUTED>                                        0


</TABLE>
I, Otto Bethlen, certify that: 

1. I have reviewed this annual report on Form 10-KSB of EZ2 Companies, Inc.:

2. Based on my knowledge, this annual report does not contain any untrue statement  of a material fact or omit to state a material fact necessary to make the statements  made, in light of the circumstances under which such statements were made, not  misleading with respect to the period covered by this annual report; 

3. Based on my knowledge, the financial statements, and other financial information  included in this annual report, fairly present in all material respects the  financial condition, results of operations and cash flows of the registrant  as of, and for, the periods presented in this annual report; 

4. The registrant’s other certifying officers and I are responsible for  establishing and maintaining disclosure controls and procedures (as defined  in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have: 

a) Designed such disclosure controls and procedures to ensure that material  information relating to the registrant, including its consolidated subsidiaries,  is made known to us by others within those entities, particularly during the  period in which this annual report is being prepared; 

b) Evaluated the effectiveness of the registrant’s disclosure controls  and procedures as of a date within 90 days prior to the filing date of this  annual report (the “Evaluation Date”); and 

c) Presented in this annual report our conclusions about the effectiveness  of the disclosure controls and procedures based on our evaluation as of the  Evaluation Date; 

5. The registrant’s other certifying officers and I have disclosed, based  on our most recent evaluation, to the registrant’s auditors and the audit  committee of registrant’s board of directors (or persons performing the  equivalent functions): 

a) All significant deficiencies in the design or operation of internal controls  which could adversely affect the registrant’s ability to record, process,  summarize and report financial data and have identified for the registrant’s  auditors any material weaknesses in internal controls; and 

b) Any fraud, whether or not material, that involves management or other employees  who have a significant role in the registrant’s internal controls; and

6. The registrant’s other certifying officers and I have indicated in  this annual report whether or not there were significant changes in internal  controls or in other factors that could significantly affect internal controls  subsequent to the date of our most recent evaluation, including any corrective  actions with regard to significant deficiencies and material weaknesses. 

  Date: April 30, 2005  /S/ OTTO. BETHLEN

--------------------------------------------------------------------------------  Chief Executive Officer